WO2009069668A1 - Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation - Google Patents

Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation Download PDF

Info

Publication number
WO2009069668A1
WO2009069668A1 PCT/JP2008/071469 JP2008071469W WO2009069668A1 WO 2009069668 A1 WO2009069668 A1 WO 2009069668A1 JP 2008071469 W JP2008071469 W JP 2008071469W WO 2009069668 A1 WO2009069668 A1 WO 2009069668A1
Authority
WO
WIPO (PCT)
Prior art keywords
expression
agent
increasing
malignant melanoma
melanoma antigen
Prior art date
Application number
PCT/JP2008/071469
Other languages
English (en)
Japanese (ja)
Inventor
Michihiro Kono
Yasushi Tomita
Original Assignee
National University Corporation Nagoya University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Nagoya University filed Critical National University Corporation Nagoya University
Priority to JP2009543831A priority Critical patent/JP5397692B2/ja
Publication of WO2009069668A1 publication Critical patent/WO2009069668A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention porte sur des moyens qui sont efficaces pour le traitement du mélanome. De façon spécifique, l'invention porte sur un agent pour augmenter l'expression d'un antigène du mélanome malin, qui comprend un composé choisi dans le groupe constitué par le méthotrexate, le paclitaxel, le chlorhydrate de daunorubicine (daunorubicine, HCl), le chlorhydrate de doxorubicine (doxorubicine, HCl), l'actinomycine D, la camptothécine, l'étoposide, la cytochalasine D, 3-ATA (3-amino-9-thio(10H)-acridone), l'aphidicoline, le bisindolylmaléimide I, un arabino nucléoside (cytosine arabinoside), le curcumin, le 2',3'-didésoxythymidine triphosphate (2',3'-didésoxythymidine 5'-triphosphate), un dimère de la thymidine (acide dipyrimidine dithymidylique), le phosphate de pyridoxal (pyridoxal 5'-phosphate hydrate), le gallate d'épigallocatechine ((-)-épigallocatechine gallate), la vidarabine, le resvératrol et l'acide lithocholique.
PCT/JP2008/071469 2007-11-28 2008-11-26 Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation WO2009069668A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009543831A JP5397692B2 (ja) 2007-11-28 2008-11-26 悪性黒色腫抗原の発現上昇剤及びその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007307905 2007-11-28
JP2007-307905 2007-11-28
JP2008124220 2008-05-12
JP2008-124220 2008-05-12

Publications (1)

Publication Number Publication Date
WO2009069668A1 true WO2009069668A1 (fr) 2009-06-04

Family

ID=40678561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071469 WO2009069668A1 (fr) 2007-11-28 2008-11-26 Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation

Country Status (2)

Country Link
JP (1) JP5397692B2 (fr)
WO (1) WO2009069668A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121097A (ja) * 2014-12-25 2016-07-07 有限会社イムノ 免疫応答を誘導するための薬剤
WO2018038425A1 (fr) * 2016-08-24 2018-03-01 (주)아모레퍼시픽 Composition de blanchiment de la peau contenant de la cytochalasine d
WO2019228108A1 (fr) * 2018-05-28 2019-12-05 福建师范大学 Composition de réactif utilisée pour augmenter l'efficacité de transfection cellulaire
US11111493B2 (en) 2018-03-15 2021-09-07 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289524A (ja) * 1985-02-01 1987-12-16 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ ヒトの神経外胚葉性悪性腫瘍と上皮性ガンの治療法
JPH03505744A (ja) * 1989-04-28 1991-12-12 シラキューズ　ユニバーシティ サイトカラシン組成物および治療法
JPH04264083A (ja) * 1991-02-15 1992-09-18 Nippon Mektron Ltd アフィディコラン誘導体およびその製造法
JPH08268917A (ja) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
JP2003515535A (ja) * 1999-11-16 2003-05-07 ザ ゼネラル ホスピタル コーポレーション 腫瘍関連抗原発現を調節するための組成物および方法
WO2004019886A2 (fr) * 2002-08-29 2004-03-11 Cytocure Llc Procedes de regulation positive de l'expression antigenique dans des tumeurs
WO2004087941A1 (fr) * 2002-02-15 2004-10-14 The General Hospital Corporation Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs
JP2006523206A (ja) * 2003-03-27 2006-10-12 メディキュア インコーポレーテッド 細胞死の調節
WO2006122431A1 (fr) * 2005-05-19 2006-11-23 Prometic Biosciences Inc. Composes de triazine et leurs compositions utilises dans le traitement des cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155239A (ja) * 1985-12-27 1987-07-10 Rikagaku Kenkyusho アフイデイコリン誘導体及びその合成法並びに制癌剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289524A (ja) * 1985-02-01 1987-12-16 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ ヒトの神経外胚葉性悪性腫瘍と上皮性ガンの治療法
JPH03505744A (ja) * 1989-04-28 1991-12-12 シラキューズ　ユニバーシティ サイトカラシン組成物および治療法
JPH04264083A (ja) * 1991-02-15 1992-09-18 Nippon Mektron Ltd アフィディコラン誘導体およびその製造法
JPH08268917A (ja) * 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
JP2003515535A (ja) * 1999-11-16 2003-05-07 ザ ゼネラル ホスピタル コーポレーション 腫瘍関連抗原発現を調節するための組成物および方法
WO2004087941A1 (fr) * 2002-02-15 2004-10-14 The General Hospital Corporation Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs
WO2004019886A2 (fr) * 2002-08-29 2004-03-11 Cytocure Llc Procedes de regulation positive de l'expression antigenique dans des tumeurs
JP2006523206A (ja) * 2003-03-27 2006-10-12 メディキュア インコーポレーテッド 細胞死の調節
WO2006122431A1 (fr) * 2005-05-19 2006-11-23 Prometic Biosciences Inc. Composes de triazine et leurs compositions utilises dans le traitement des cancers

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Annals of the New York Academy of Sciences", vol. 446, 1985, article GHOSE, T. ET AL.: "Antibodies as carriers of cancer chemotherapeutic agents", pages: 213 - 227 *
AOYAGI, Y. ET AL.: "In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 90, no. 5, 1999, pages 578 - 587 *
AQUINO, A. ET AL.: "Drug-induced increase of carcinoembryonic antigen expression in cancer cells", PHARMACOLOGICAL RESEARCH, vol. 49, no. 5, 2004, pages 383 - 396 *
ARNOULD, R. ET AL.: "Compared cytotoxicity effects of five anticancer drugs on human (HBL) and mouse (B16) melanoma cells in vitro", ANTICANCER RESEARCH, vol. 10, no. 3, 1990, pages 789 - 793 *
BAJETTA, E. ET AL.: "Metastatic melanoma: chemotherapy", SEMINARS IN ONCOLOGY, vol. 29, no. 5, 2002, pages 427 - 445 *
BUSH, J.A. ET AL.: "Curcumin induces apoptosis in human melanoma cells through a Fas receptor/ caspase-8 pathway independent of p53", EXPERIMENTAL CELL RESEARCH, vol. 271, no. 2, 2001, pages 305 - 314 *
CHEMICAL ABSTRACTS, vol. 142, 2005, Columbus, Ohio, US; abstract no. 142:273591R *
CHOPRA, H. ET AL.: "An in vivo study of the role of the tumor cell cytoskeleton in tumor cell- platelet-endothelial cell interactions", CANCER RESEARCH, vol. 50, no. 23, 1990, pages 7686 - 7696 *
DICCIANNI, M.B. ET AL: "3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner", JOURNAL OF EXPERIMENTAL THERAPEUTICS & ONCOLOGY, vol. VOL.4, no. NO.3, 2004, pages 223 - 237 *
HSIEH, T.C. ET AL.: "Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 334, no. 1, 2005, pages 223 - 230 *
KAZUKI NAKAMURA ET AL.: "C Kinase Sogaizai ni yoru p53 Tanpaku Rin Sanka o Kaishita Gan Saibo Kino Yokusei", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 12, 2000, pages 1387 - 1394 *
KONO, M. ET AL.: "Aphidicolin as a possible modulating agent for melanoma antigen expression in melanoma immunotherapy", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 128, no. SUP 1, April 2008 (2008-04-01), pages S219 *
KONO, M. ET AL.: "Methotrexate as a possible modulating agent for melanoma antigen expression in melanoma immunotherapy", PIGMENT CELL & MELANOMA RESEARCH, vol. 21, no. 2, April 2008 (2008-04-01), pages 324 - 325 *
LEPAGE, G.A. ET AL.: "Responses of patients to arabinosyladenine-5'-phosphate correlated with an in vitro test", ADVANCES IN ENZYME REGULATION, vol. 17, 1978, pages 437 - 454 *
LIN, J.D. ET AL.: "Inhibition of melanoma growth and metastasis by combination with (-)- epigallocatechin-3-gallate and dacarbazine in mice", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 83, no. 4, 2001, pages 631 - 642 *
MAEDA, N. ET AL.: "Effects of DNA polymerase inhibitory and antitumor activities of lipase- hydrolyzed glycolipid fractions from spinach", THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 16, 2005, pages 121 - 128 *
MONTI, E. ET AL.: "Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1180, no. 3, 1993, pages 231 - 235 *
NEALE, M.H. ET AL.: "Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside", BRITISH JOURNAL OF CANCER, vol. 79, no. 9-10, 1999, pages 1487 - 1493 *
PANTAZIS, P. ET AL.: "Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins", CANCER RESEARCH, vol. 52, no. 14, 1992, pages 3980 - 3987 *
SHULTZ, T.D. ET AL.: "Effect of pyridoxine and pyridoxal on the in vitro growth of human malignant melanoma", ANTICANCER RESEARCH, vol. 8, no. 6, 1988, pages 1313 - 1318 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016121097A (ja) * 2014-12-25 2016-07-07 有限会社イムノ 免疫応答を誘導するための薬剤
WO2018038425A1 (fr) * 2016-08-24 2018-03-01 (주)아모레퍼시픽 Composition de blanchiment de la peau contenant de la cytochalasine d
KR20180022416A (ko) * 2016-08-24 2018-03-06 (주)아모레퍼시픽 사이토칼라신 d를 포함하는 피부 미백용 조성물
KR102600091B1 (ko) 2016-08-24 2023-11-09 (주)아모레퍼시픽 사이토칼라신 d를 포함하는 피부 미백용 조성물
US11111493B2 (en) 2018-03-15 2021-09-07 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11421228B2 (en) 2018-03-15 2022-08-23 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11608500B2 (en) 2018-03-15 2023-03-21 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019228108A1 (fr) * 2018-05-28 2019-12-05 福建师范大学 Composition de réactif utilisée pour augmenter l'efficacité de transfection cellulaire

Also Published As

Publication number Publication date
JP5397692B2 (ja) 2014-01-22
JPWO2009069668A1 (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
HK1146410A1 (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
WO2007089768A3 (fr) 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisées comme modulateurs de la jak-2 et leurs procédés d'utilisation
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008039489A3 (fr) Dérivés de quinazolinone substitués en 5', compositions contenant ces dérivés et procédés d'utilisation
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2009026179A3 (fr) Composés de proanthocyanidine anti-infectieux et leurs procédés d'utilisation
WO2008089105A3 (fr) Analogues de nucléosides antiviraux
MY184464A (en) Combined use of cholestanol derivative
WO2008049116A3 (fr) Indoles substitués
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
WO2007140385A3 (fr) Nouveaux composés en tant que ligands des récepteurs des cannabinoïdes et utilisations de ceux-ci
WO2007121918A3 (fr) Composés organiques
WO2009073506A3 (fr) Promédicaments nucléosidiques et leurs utilisations
WO2008075201A3 (fr) Compositions d'épigallocatéchine-3-gallate destinées au traitement du cancer et à la chimioprotection
WO2007054100A3 (fr) Phosphoramidates du nucléoside lna
WO2008008700A3 (fr) Composés thérapeutiques
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
WO2009069668A1 (fr) Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation
CA2659376C (fr) 2,4-diaminoquinazolines contre l'amyotrophie spinale
WO2010080414A3 (fr) Dérivés de fno (2-[furane-2-yl] naphthalène-1-ol) substitués utilisés comme agents anticancéreux
IL223327A0 (en) 5,6 or 7-substituted-s- (hetero) arylisoquinolinamine derivatives as antitumor agents
EP2251014A4 (fr) Utilisation combinée de dérivé du cholestanol
WO2006078887A3 (fr) Derives de methylphenidate et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854988

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009543831

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854988

Country of ref document: EP

Kind code of ref document: A1